Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TRDA |
---|---|---|
09:32 ET | 1335 | 14.13 |
09:36 ET | 194 | 14.25 |
09:38 ET | 9943 | 14.23 |
09:39 ET | 100 | 14.085 |
09:41 ET | 200 | 14.29 |
09:43 ET | 2025 | 14.53 |
09:45 ET | 1000 | 14.57 |
09:50 ET | 100 | 14.565 |
09:52 ET | 300 | 14.55 |
09:54 ET | 100 | 14.55 |
09:56 ET | 370 | 14.56 |
09:57 ET | 100 | 14.675 |
10:06 ET | 200 | 14.74 |
10:10 ET | 100 | 14.8 |
10:12 ET | 300 | 14.95 |
10:26 ET | 1100 | 14.78 |
10:30 ET | 365 | 14.82 |
10:32 ET | 2046 | 14.94 |
10:33 ET | 900 | 15.065 |
10:35 ET | 344 | 15.083 |
10:37 ET | 100 | 15.09 |
10:39 ET | 325 | 15.02 |
10:42 ET | 100 | 15 |
10:46 ET | 300 | 14.91 |
10:48 ET | 100 | 14.915 |
10:50 ET | 200 | 14.905 |
10:53 ET | 200 | 14.925 |
10:55 ET | 100 | 14.93 |
10:57 ET | 707 | 14.985 |
11:00 ET | 627 | 14.92 |
11:06 ET | 389 | 14.92 |
11:08 ET | 100 | 14.92 |
11:20 ET | 200 | 14.98 |
11:22 ET | 100 | 15 |
11:24 ET | 400 | 15.08 |
11:27 ET | 300 | 15 |
11:29 ET | 100 | 14.99 |
11:33 ET | 100 | 15.045 |
11:36 ET | 100 | 15.045 |
11:38 ET | 239 | 14.99 |
11:42 ET | 500 | 15.12 |
11:44 ET | 100 | 15.07 |
11:45 ET | 100 | 15.12 |
11:47 ET | 100 | 15.12 |
11:56 ET | 333 | 15.1 |
11:58 ET | 764 | 15.07 |
12:07 ET | 100 | 15.075 |
12:14 ET | 100 | 15.01 |
12:16 ET | 200 | 15.045 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Entrada Therapeutics Inc | 507.8M | 5.1x | --- |
Heron Therapeutics Inc | 295.8M | -6.4x | --- |
Alector Inc | 548.9M | -3.4x | --- |
WAVE Life Sciences Ltd | 682.3M | -10.2x | --- |
Avid Bioservices Inc | 728.5M | -5.5x | --- |
Kamada Ltd | 302.9M | 18.3x | -22.48% |
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $507.8M |
---|---|
Revenue (TTM) | $239.4M |
Shares Outstanding | 37.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $2.96 |
Book Value | $7.25 |
P/E Ratio | 5.1x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | 4.7x |
Operating Margin | 39.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.